NCT01407003View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

LIK066

Participants will receive a single or multiple doses of LIK066

DRUG

Placebo

Participants will receive a single or multiple doses of a matching placebo

Trial Locations (1)

33126

Novartis Investigative Site, Miami

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY